"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
Overdosage has not been reported with NebuPent (pentamidine isethionate) . The symptoms and signs of overdosage are not known.
A serious overdosage, to the point of producing systemic drug levels similar to those following parenteral administration, would have the potential of producing similar types of serious systemic toxicity. (See PRECAUTIONS).
Available clinical pharmacology data (see CLINICAL PHARMACOLOGY) suggest that a dose up to 40 times the recommended NebuPent (pentamidine isethionate) dosage would be required to produce systemic levels similar to a single 4 mg/kg intravenous dose.
NebuPent (pentamidine isethionate) is contraindicated in patients with a history of an anaphylactic reaction to inhaled or parenteral pentamidine isethionate.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 4/4/2011
Additional Nebupent Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.